Durable progression-free survival benefit in early responders to elotuzumab plus lenalidomide and dexamethasone (ELd): analysis of ELOQUENT-2 4-year data in relapsed/refractory (RR) multiple myeloma (MM)

被引：0

作者：

Scheid, C. ^{[1
]}

Roellig, C. ^{[2
]}

Weisel, K. ^{[3
]}

Salwender, H-J ^{[4
]}

Gramatzki, M. ^{[5
]}

Edmaier-Schroeger, K. ^{[6
]}

Sy, O. ^{[7
]}

Goldschmidt, H. ^{[8
]}

机构：

[1] Univ Klinikum Koln, Cologne, Germany

[2] Univ Dresden, Dresden, Germany

[3] Univ Tubingen, Tubingen, Germany

[4] Asklepios Klin Hamburg, Hamburg, Germany

[5] Univ Schleswig Holstein, Kiel, Germany

[6] Bristol Myers Squibb, Munich, Germany

[7] Bristol Myers Squibb, Princeton, NJ USA

[8] Heidelberg Univ, Natl Ctr Tumor Dis, Heidelberg, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P571

引用

页码：189 / 189

页数：1

共 50 条

[41] Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial
Kazandjian, Dickran
Korde, Neha
Mailankody, Sham
Hill, Elizabeth
Figg, William D.
Roschewski, Mark
Landgren, Ola
JAMA ONCOLOGY, 2018, 4 (12) : 1781 - 1783
[42] Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies
Fu, Weijun
Lu, Jin
Jin, Jie
Xu, Yan
Wu, Depei
Zhou, Dao-bin
Ke, Xiaoyan
Du, Xin
Chen, Xiequn
Chng, Wee Joo
Kim, Kihyun
Li, Junmin
Lee, Jae Hoon
Liu, Jing
Goh, Yeow Tee
Wu, Kwang-Wei
Wang, Hui
Liu, Guohui
Skacel, Tomas
Wan, Hui
Berg, Deborah
BLOOD, 2018, 132
[43] Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) after lenalidomide (LEN)-based second-line (2L) treatment (Tx) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): Analysis of progression-free survival (PFS) by level of disease control.
Siegel, David
Schiller, Gary J.
Song, Kevin W.
Agajanian, Richy
Stockerl-Goldstein, Keith
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[44] Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1
Bringhen, Sara
Voorhees, Peter M.
Plesner, Torben
Mellqvist, Ulf-Henrik
Reeves, Brandi
Sonneveld, Pieter
Byrne, Catriona
Nordstrom, Eva
Harmenberg, Johan
Obermueller, Jakob
Richardson, Paul G.
BLOOD, 2019, 134
[45] Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)
Moreau, Philippe
Masszi, Tunas
Grzasko, Norbert
Bahlis, Nizar J.
Hansson, Markus
Pour, Ludek
Sandhu, Irwindeep
Ganly, Peter
Baker, Bartrum W.
Jackson, Sharon
Stoppa, Anne -Marie
Simpson, David R.
Gimsing, Peter
Palumbo, Antonio
Garderet, Laurent
Cavo, Michele
Kumar, Shaji K.
Touzeau, Cyrille
Buadi, Francis
Laubach, Jacob P.
Lin, Jianchang
Berg, Deborah
DiBacco, Alessandra
Hui, Ai -Min
Richardson, Paul G.
BLOOD, 2015, 126 (23)
[46] Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study
Rifkin, Robert M.
Melear, Jason M.
Faber, Edward
Bensinger, William I.
Burke, John M.
Narang, Mohit
Stevens, Don
Gunawardena, Sriya
Lutska, Yana
Qi, Keqin
Ukropec, Jon
Qi, Ming
Lin, Thomas S.
Yimer, Habte A.
BLOOD, 2019, 134
[47] Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function.
Weber, Donna
Wang, Michael
Chen, Christine
Belch, Andrew
Stadtmauer, Edward A.
Niesvisky, Ruben
Yu, Zhinuan
Olesnyckyj, Marta
Zeldis, Jerome
Knight, Robert D.
Dimopoulos, Meletios
BLOOD, 2006, 108 (11) : 1012A - 1013A
[48] Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM)
Garderet, Laurent
Laubach, Jacob P.
Stoppa, Anne-Marie
Hari, Parameswaran
Cavo, Michele
Ludwig, Heinz
Mateos, Maria-Victoria
Luptakova, Katarina
Lin, Jianchang
van de Velde, Helgi
Berg, Deborah
Moreau, Philippe
Richardson, Paul G.
BLOOD, 2016, 128 (22)
[49] Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies
Chng, Wee-Joo
Lonial, Sagar
Morgan, Gareth J.
Iida, Shinsuke
Moreau, Philippe
Kumar, Shaji
Twumasi-Ankrah, Philip
Kumar, Arun
Dash, Ajeeta B.
Vorog, Alexander
Zhang, Xiaoquan
Suryanarayan, Kaveri
Labotka, Richard
Dimopoulos, Meletios A.
Rajkumar, S. Vincent
BLOOD, 2021, 138
[50] Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD plus Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts
Paiva, Bruno
Manrique, Irene
Giuliani, Nicola
Cavo, Michele
Rojas, Christine
Fu, Weijun
Mateos, Maria-Victoria
Dimopoulos, Meletios A.
Vorog, Alexander
Li, Cong
Wang, Bingxia
Labotka, Richard J.
Dash, Ajeeta B.
BLOOD, 2020, 136

← 1 2 3 4 5 →